Decaux G, Soupart A, Vassart G (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371(9624):1624–1632. https://doi.org/10.1016/s0140-6736(08)60695-9

Article  CAS  PubMed  Google Scholar 

Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297(12):1332–1343. https://doi.org/10.1001/jama.297.12.1332

Article  CAS  PubMed  Google Scholar 

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12):1319–1331. https://doi.org/10.1001/jama.297.12.1319

Article  CAS  PubMed  Google Scholar 

Xiong B, Huang Y, Tan J, Yao Y, Wang C, Qian J, Rong S, Deng S, Cao Y, Zou Y, Huang J (2015) The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev 20(6):633–642. https://doi.org/10.1007/s10741-015-9503-x

Article  CAS  PubMed  Google Scholar 

Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson LW (2003) Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41(10):1797–1804

Article  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368

Article  CAS  PubMed  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895–e1032. https://doi.org/10.1161/cir.0000000000001063

Article  PubMed  Google Scholar 

Thomas SS, Nohria A (2012) Hemodynamic classifications of acute heart failure and their clinical application: - an update. Circ J 76(2):278–286

Article  PubMed  Google Scholar 

Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr (2006) Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290(2):F273-278. https://doi.org/10.1152/ajprenal.00195.2005

Article  CAS  PubMed  Google Scholar 

Hedrich O, Konstam MA, Udelson JE (2006) The role of vasopressin and vasopressin antagonists in heart failure. In: Feldman AM (ed) Heart failure : Pharmacologic Management. Blackwell Pub, pp 185–202

Google Scholar 

Sanghi P, Uretsky BF, Schwarz ER (2005) Vasopressin antagonism: a future treatment option in heart failure. Eur Heart J 26(6):538–543. https://doi.org/10.1093/eurheartj/ehi145

Article  CAS  PubMed  Google Scholar 

Sears E, Brooks S (2010) New drugs approved in 2009. Proc (Bayl Univ Med Cent) 23(2):175–183

PubMed  Google Scholar 

Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ (2013) Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 126(10 Suppl 1):S1-42. https://doi.org/10.1016/j.amjmed.2013.07.006

Article  PubMed  Google Scholar 

Kanaya M, Matsushita K, Inami T, Yamasaki S, Mizumi S, Minamishima T, Goda A, Ueda A, Sakata K, Satoh T, Yoshino H (2016) Successful Treatment of Severe Right-Sided Heart Failure Due to Postoperative Constrictive Pericarditis With Tolvaptan. Am J Ther 23(1):e264-267. https://doi.org/10.1097/mjt.0000000000000146

Article  PubMed  Google Scholar 

Jamookeeah C, Robinson P, O’Reilly K, Lundberg J, Gisby M, Landin M, Skov J, Trueman D (2016) Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. BMC Endocr Disord 16(1):22. https://doi.org/10.1186/s12902-016-0104-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pose A, Almenar L, Gavira JJ, Lopez-Granados A, Blasco T, Delgado J, Aramburu O, Rodriguez A, Manzano L, Manito N (2017) Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic-refractory congestive heart failure: the SEMI-SEC project. ESC Heart Fail 4(2):130–137. https://doi.org/10.1002/ehf2.12124

Article  PubMed  PubMed Central  Google Scholar 

Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Wiecek A, Zoccali C, Van Biesen W (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31(3):337–348. https://doi.org/10.1093/ndt/gfv456

Article  PubMed  PubMed Central  Google Scholar 

Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE (2018) A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol 29(10):2458–2470. https://doi.org/10.1681/asn.2018060590

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsushita K, Harada K, Miyazaki T, Miyamoto T, Kohsaka S, Iida K, Tanimoto S, Yagawa M, Shiraishi Y, Yoshino H, Yamamoto T, Nagao K, Takayama M (2017) Effect of Heart Failure Secondary to Ischemic Cardiomyopathy on Body Weight and Blood Pressure. Am J Cardiol 120(9):1589–1594. https://doi.org/10.1016/j.amjcard.2017.07.054

Article  PubMed  Google Scholar 

Matsushita K, Harada K, Miyazaki T, Miyamoto T, Kohsaka S, Iida K, Tanimoto S, Takei M, Hosoda T, Yamamoto Y, Shiraishi Y, Yoshino H, Yamamoto T, Nagao K, Takayama M (2019) Different prognostic associations of beta-blockers and diuretics in heart failure with preserved ejection fraction with versus without high blood pressure. J Hypertens 37(3):643–649. https://doi.org/10.1097/hjh.0000000000001932

Article  CAS  PubMed  Google Scholar 

Matsushita K, Harada K, Miyazaki T, Miyamoto T, Kohsaka S, Iida K, Yamamoto Y, Nagatomo Y, Yoshino H, Yamamoto T, Nagao K, Takayama M (2019) Younger- vs Older-Old Patients with Heart Failure with Preserved Ejection Fraction. J Am Geriatr Soc 67(10):2123–2128. https://doi.org/10.1111/jgs.16050

Article  PubMed  Google Scholar 

Matsushita K, Harada K, Kohno T, Nakano H, Kitano D, Matsuda J, Takei M, Yoshino H, Yamamoto T, Nagao K, Takayama M (2024) Prevalence and clinical characteristics of diabetic cardiomyopathy in patients with acute heart failure. Nutr Metab Cardiovasc Dis 34(5):1325–1333. https://doi.org/10.1016/j.numecd.2023.12.013

Article  CAS  PubMed  Google Scholar 

Matsushita K, Harada K, Kohno T, Nakano H, Kitano D, Matsuda J, Yoshino H, Yamamoto T, Nagao K, Takayama M (2024) Comparison of clinical characteristics and prognostic factors in patients with heart failure with preserved ejection fraction with and without renal dysfunction. Minerva Cardiol Angiol. https://doi.org/10.23736/s2724-5683.24.06510-4

Article  PubMed  Google Scholar 

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982–992. https://doi.org/10.1053/j.ajkd.2008.12.034

Article  CAS  PubMed  Google Scholar 

Rosenbaum PR (2010) Sensitivity to hidden bias. In: Rosenbaum PR (ed) Observational studies, 2nd edn. Springer-Verlag, pp 105–170

Chapter  Google Scholar 

Eshaghian S, Horwich TB, Fonarow GC (2006) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97(12):1759–1764. https://doi.org/10.1016/j.amjcard.2005.12.072

Article  CAS  PubMed  Google Scholar 

Matsushita K (2016) Pathogenetic pathways of cardiorenal syndrome and their possible therapeutic implications. Curr Pharm Des 22(30):4629–4637. https://doi.org/10.2174/1381612822666160510125057

Article  CAS  PubMed